Die Ophthalmologie最新文献_第3页

[Corneal events with mirvetuximab soravtansine : A review of ocular surface events associated with the tubulin-acting antibody-drug conjugate, mirvetuximab soravtansine]. [mirvetuximab soravtansine的角膜事件：与微管蛋白作用抗体-药物偶联物mirvetuximab soravtansine相关的眼表面事件的回顾]。

IF 0.6

Die Ophthalmologie Pub Date : 2025-10-01 Epub Date: 2025-09-02 DOI: 10.1007/s00347-025-02306-7

Ramin Khoramnia, Gerald Schmidinger

{"title":"[Corneal events with mirvetuximab soravtansine : A review of ocular surface events associated with the tubulin-acting antibody-drug conjugate, mirvetuximab soravtansine].","authors":"Ramin Khoramnia, Gerald Schmidinger","doi":"10.1007/s00347-025-02306-7","DOIUrl":"10.1007/s00347-025-02306-7","url":null,"abstract":"Antibody-drug conjugates (ADC) are a class of targeted anticancer therapy that consist of a monoclonal antibody (linker) and a cytotoxic substance. Ocular adverse events (AEs) are common among ADCs with tubulin-targeted active agents, such as belantamab mafodotin, tisotumab vedotin and mirvetuximab soravtansine (MIRV). The substance MIRV targets folate receptor alpha (FRalpha) and has a tubulin-acting agent (the maytansinoid DM4). The use of MIRV received full approval in the USA (March 2024) for FRalpha-positive platinum-resistant ovarian cancer (PROC) and is the first novel agent to demonstrate a significant survival advantage against single agent chemotherapy in a phase 3 PROC trial. The use of MIRV was recently approved by the European Medicines Agency (EMA) for the same indication, as assessed in the MIRASOL trial. Ocular AEs associated with MIRV primarily include blurred vision and keratopathy, due to transient corneal alterations; however, the mechanism by which MIRV causes ocular AEs is thought to be a result of \"off-target\" effects or non-specific uptake by corneal epithelial cells. Results from clinical trials of MIRV demonstrate that these AEs can be resolved and monitoring/prophylactic strategies are in place to mitigate their incidence, including prophylactic corticosteroid eye drops, daily lubricating eye drops, dose modifications and regular ocular examinations. Support from ophthalmologists is essential to AE management to allow MIRV therapy to continue. This review provides ophthalmologists with a clinical overview of ocular AEs associated with certain tubulin-acting ADCs, with a focus on MIRV, and the prophylactic/mitigative measures that can allow patients to stay on MIRV therapy longer.","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":"803-812"},"PeriodicalIF":0.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144980916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Assessment of myopia progression]. [近视进展评估]。

IF 0.6

Die Ophthalmologie Pub Date : 2025-10-01 Epub Date: 2025-07-21 DOI: 10.1007/s00347-025-02276-w

Navid Farassat, Wolf A Lagrèze

引用次数: 0

[DMEK for endothelial decompensation after penetrating keratoplasty]. [穿透性角膜移植术后内皮失代偿的DMEK]。

IF 0.6

Die Ophthalmologie Pub Date : 2025-10-01 Epub Date: 2025-08-29 DOI: 10.1007/s00347-025-02310-x

Thomas Hammer, Arne Viestenz, Christiane Kesper, Anja Viestenz

{"title":"[DMEK for endothelial decompensation after penetrating keratoplasty].","authors":"Thomas Hammer, Arne Viestenz, Christiane Kesper, Anja Viestenz","doi":"10.1007/s00347-025-02310-x","DOIUrl":"10.1007/s00347-025-02310-x","url":null,"abstract":"Background: In recent years, the Descemet membrane endothelial keratoplasty (DMEK) has become the standard transplantation procedure for endothelial corneal diseases due to faster visual recovery and lower graft rejection rates compared to penetrating keratoplasty (pKPL). Endothelial corneal decompensation after pKPL is also a possible indication for DMEK. The question is which intraoperative and postoperative aspects need to be considered.Methods: We retrospectively reviewed the DMEK surgeries performed in our clinic in 2020 and 2021 after pKPL (n = 10) regarding intraoperative and postoperative characteristics as well as functional and morphological results.Results: Of the 10 eyes analyzed a repeat pKPL could be avoided by DMEK in 7 cases. The initial situation of the eyes was very different with respect to corneal decompensation, the primary indications for pKPL and number of previous pKPLs. The rate of postoperative gas re-injections (re-bubblings) was 80%, in some cases requiring multiple gas injections. A 20% sulphur hexafluoride (SF6) gas-air mixture was used for gas endotamponade. The improvement in visual acuity was highly variable. Overall, visual acuity in the treated eyes increased by 5.1 ± 1.4 lines after DMEK in the pKPL eyes (p < 0.001, minimum 3 lines, maximum 7 lines; logMAR preoperative 1.48 ± 0.36 to logMAR postoperative 0.57 ± 0.28).Conclusion: The use of DMEK for endothelial graft failure after pKPL is a possible minimally invasive procedure to avoid repeat pKPL. The postoperative follow-up requires significantly more re-bubblings due to the altered anatomical situation and geometry of the posterior corneal surface after pKPL and the resulting poorer adhesion of Descemet's lamella.","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":"826-832"},"PeriodicalIF":0.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144980858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[My year with the DOG Leadership Academy]. [我在DOG领导学院的一年]。

IF 0.6

Die Ophthalmologie Pub Date : 2025-10-01 Epub Date: 2025-05-22 DOI: 10.1007/s00347-025-02260-4

Mariya Gosheva

引用次数: 0

[Ophthalmology online : Representation of the discipline ophthalmology on instagram]. 【眼科学在线：眼科学在instagram上的表现】。

IF 0.6

Die Ophthalmologie Pub Date : 2025-10-01 Epub Date: 2025-08-25 DOI: 10.1007/s00347-025-02286-8

Maja Tabea Jerrentrup, Volker Besgen, Walter Sekundo

引用次数: 0

[Recognition in ophthalmology: the Sicca Advancement Award 1999-2024]. [眼科认可：1999-2024年Sicca进步奖]。

IF 0.6

Die Ophthalmologie Pub Date : 2025-09-29 DOI: 10.1007/s00347-025-02327-2

Leander Scheel, Thorsten Halling, Giacomo Padrini, Nils Hansson

{"title":"[Recognition in ophthalmology: the Sicca Advancement Award 1999-2024].","authors":"Leander Scheel, Thorsten Halling, Giacomo Padrini, Nils Hansson","doi":"10.1007/s00347-025-02327-2","DOIUrl":"https://doi.org/10.1007/s00347-025-02327-2","url":null,"abstract":"The Sicca Advancement Award has been awarded annually for clinical and basic work in the field of dry eye research. The aim of this study is to analyze the internal structures, networks, and selection processes of Sicca Award winners using qualitative and quantitative methods. The study is based on original documents, calls for applications, meeting minutes (1999-2024), and interviews with jury members. Of a total of 360 applications (1999-2024), more than half (54%) were awarded a prize. There has been a steady increase in the number of female applicants and prize winners. Düsseldorf, Erlangen, and Cologne were identified as particularly successful research locations. Jury members often serve for long periods of time. Since 2014 at the latest, jury members have not participated in the discussion or voting for applicants from their own institution. On average, €2,497.27 prize money is awarded, which is too low to directly promote research. Rather, the Sicca Award is a funding and networking tool. The award has raised awareness in the field of dry eye research and ensured its place in German ophthalmology. Thanks to extensive marketing, the Sicca Advancement Award is more prominent than many other awards in ophthalmology.","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145193813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Publisher Erratum zu: Zentralvenenverschluss bei Marathon Runner’s Retinopathy. “马拉松运动员视网膜病变的中央静脉阻塞”。

IF 0.6

Die Ophthalmologie Pub Date : 2025-09-26 DOI: 10.1007/s00347-025-02331-6

Katja Steffen, Mareike Rockel, Burkhard von Jagow

引用次数: 0

[Direct selective laser trabeculoplasty for glaucoma]. 直接选择性激光小梁成形术治疗青光眼。

IF 0.6

Die Ophthalmologie Pub Date : 2025-09-22 DOI: 10.1007/s00347-025-02315-6

Tim Schultz, Atanas Bogoev, H Burkhard Dick

引用次数: 0

[Microcystic macular edema as biomarker for multiple sclerosis]. [微囊性黄斑水肿作为多发性硬化的生物标志物]。